TY - JOUR AU - Riani, fety AU - Dewayani, Birgitta Maria AU - Yulianti, Herry AU - Hernowo, Bethy Surjawathy AU - Suryanti, Sri PY - 2019/04/18 Y2 - 2024/03/29 TI - High Expression of CXCR4, Instead of PD-L1, Is Correlated with Poor Clinical Response to R-CHOP Therapy in Diffuse Large B-cell Lymphoma Patients JF - International Journal of Medical Science and Clinical Invention JA - ijmsci VL - 6 IS - 04 SE - Research Article DO - 10.18535/ijmsci/v6i4.04 UR - https://valleyinternational.net/index.php/ijmsci/article/view/2040 SP - 4411-4416 AB - <p><strong>Background:</strong> Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin Lymphoma worldwide. Rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine and prednisone (R-CHOP) are the current standard therapy. About 10% cases of DLBCL were refractory to these immunochemotherapy and may have poor prognosis. Latest studies showed that C-X-C chemokine receptor type 4 (CXCR4) and Programmed Death Ligand 1 (PD-L1) were involved in DLBCL biology and correlated with patients’ poor survival. This study aimed to investigate the expression of CXCR4 and PD-L1 with clinical characteristics and its response to R-CHOP in DLBCL and their potential benefit as future predictive biomarkers.</p><p><strong>Methods:</strong> Thirty four cases of newly diagnosed DLBCL were selected from Hasan Sadikin General Hospital, Bandung, Indonesia, during 2015-2018. Treatment outcome was retrieved from patients’ medical records. The expression of CXCR4 and PD-L1 in patients’ tumor &nbsp;tissues were detected using immunohistochemistry.</p><p><strong>Results: </strong>Five of 34 cases (14.70%) showed poor clinical response to R-CHOP. High CXCR4 expression was detected in 11 of 34 cases (32.35%), it was significantly correlated with clinical stage (p = 0.0003) and poor clinical response (p = 0.029). High PD-L1 expression was detected in 10 of 34 cases (29.41%) and was significantly correlated with patients’ gender (p = 0.022) but was not correlated with poor clinical response (p = 0.138).</p><p><strong>Conclusions: </strong>CXCR4 in DLBCL increased probability of poor clinical response to R-CHOP, but not PD-L1 expression. This finding provides the ground for further research which relates to &nbsp;CXCR4 as a future predictive biomarker for this challenging malignancy.</p> ER -